Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin and Metformin Initial Combination in T2DM
NCT01787396Phase 3Completed
- Sponsor
- LG Chem
- Start
- Apr 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gemigliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by LG Chem. Primary endpoint: Hemoglobin A1c at 24 weeks. Started Apr 2013; status: completed.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01787396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01787396.